Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Arthur Y Kim

Showing results (71-80 of 193) with videos related to

Pageof 20
Sort By:
BMJ Open|January 12, 2024
Virological, serological and clinical outcomes in chronic hepatitis B virus infection: development and validation of the HEPA-B simulation modelAmir M Mohareb, Arthur Y Kim, Anders Boyd, et al.
The Journal of Infectious Diseases|February 10, 2009
Temporal dynamics of a predominant protease inhibitor-resistance mutation in a treatment-naive, hepatitis C virus-infected individualArthur Y Kim, Joerg Timm, Brian E Nolan, et al.
FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology|May 1, 2020
Rethinking the role of hydroxychloroquine in the treatment of COVID-19Eric A Meyerowitz, Augustin G L Vannier, Morgan G N Friesen, et al.
Journal of Substance Abuse Treatment|June 21, 2022
Treatment for hepatitis C virus with direct acting antiviral agents: Perspectives and treatment experiences of people who inject drugsAlison Karasz, Reena Singh, M Diane McKee, et al.
Journal of the International AIDS Society|March 6, 2024
What does the scale-up of long-acting HIV pre-exposure prophylaxis mean for the global hepatitis B epidemic?Amir M Mohareb, Menan Gérard Kouamé, Marcellin Nouaman, et al.
Journal of Virology|May 22, 2002
Comprehensive analysis of CD8(+)-T-cell responses against hepatitis C virus reveals multiple unpredicted specificitiesGeorg M Lauer, Kei Ouchi, Raymond T Chung, et al.
JCI Insight|December 14, 2021
Peripheral blood iNKT cell activation correlates with liver damage during acute hepatitis CTina Senff, Christopher Menne, Christine Cosmovici, et al.
Medrxiv : the Preprint Server for Health Sciences|June 23, 2022
Nirmatrelvir plus ritonavir for early COVID-19 and hospitalization in a large US health systemScott Dryden-Peterson, Andy Kim, Arthur Y Kim, et al.
Topics in Antiviral Medicine|April 19, 2013
Impact of new therapeutics for hepatitis C virus infection in incarcerated populationsAnne S Spaulding, Arthur Y Kim, Amy Jo Harzke, et al.
Journal of Virology|October 9, 2015
Distinct Escape Pathway by Hepatitis C Virus Genotype 1a from a Dominant CD8+ T Cell Response by Selection of Altered Epitope ProcessingAndreas Walker, Kathrin Skibbe, Eike Steinmann, et al.
Pageof 20

Showing results (71-80 of 193) with videos related to

Sort By:
Pageof 20
BMJ Open|January 12, 2024
Virological, serological and clinical outcomes in chronic hepatitis B virus infection: development and validation of the HEPA-B simulation modelAmir M Mohareb, Arthur Y Kim, Anders Boyd, et al.
The Journal of Infectious Diseases|February 10, 2009
Temporal dynamics of a predominant protease inhibitor-resistance mutation in a treatment-naive, hepatitis C virus-infected individualArthur Y Kim, Joerg Timm, Brian E Nolan, et al.
FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology|May 1, 2020
Rethinking the role of hydroxychloroquine in the treatment of COVID-19Eric A Meyerowitz, Augustin G L Vannier, Morgan G N Friesen, et al.
Journal of Substance Abuse Treatment|June 21, 2022
Treatment for hepatitis C virus with direct acting antiviral agents: Perspectives and treatment experiences of people who inject drugsAlison Karasz, Reena Singh, M Diane McKee, et al.
Journal of the International AIDS Society|March 6, 2024
What does the scale-up of long-acting HIV pre-exposure prophylaxis mean for the global hepatitis B epidemic?Amir M Mohareb, Menan Gérard Kouamé, Marcellin Nouaman, et al.
Journal of Virology|May 22, 2002
Comprehensive analysis of CD8(+)-T-cell responses against hepatitis C virus reveals multiple unpredicted specificitiesGeorg M Lauer, Kei Ouchi, Raymond T Chung, et al.
JCI Insight|December 14, 2021
Peripheral blood iNKT cell activation correlates with liver damage during acute hepatitis CTina Senff, Christopher Menne, Christine Cosmovici, et al.
Medrxiv : the Preprint Server for Health Sciences|June 23, 2022
Nirmatrelvir plus ritonavir for early COVID-19 and hospitalization in a large US health systemScott Dryden-Peterson, Andy Kim, Arthur Y Kim, et al.
Topics in Antiviral Medicine|April 19, 2013
Impact of new therapeutics for hepatitis C virus infection in incarcerated populationsAnne S Spaulding, Arthur Y Kim, Amy Jo Harzke, et al.
Journal of Virology|October 9, 2015
Distinct Escape Pathway by Hepatitis C Virus Genotype 1a from a Dominant CD8+ T Cell Response by Selection of Altered Epitope ProcessingAndreas Walker, Kathrin Skibbe, Eike Steinmann, et al.
Pageof 20